Genesis Therapeutics Closes $200M Series B Funding


Genesis Therapeutics, a Burlingame, CA-based artificial intelligence (AI) tech company which specializes in medicines for patients with severe diseases, raised $200M in Series B funding.

The round was led by co-led by a U.S.-based life-sciences-focused investor, along with returning investor Andreessen Horowitz (a16z) Bio + Health which led the company’s seed financing. In addition, other new investors participated in the Series B including Fidelity Management & Research Company, BlackRock, and NVIDIA’s venture capital arm NVentures, along with existing investors T. Rowe Price Associates, Inc., Rock Springs Capital, Radical Ventures, and Menlo Ventures.

The company intends to use the funds to further invest in its AI platform, and expand its discovery pipeline.

Led by CEO Evan Feinberg, Genesis Therapeutics is unifying AI and biotechnology to discover novel treatments for patients with severe and devastating conditions. It uses a proprietary generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), which integrates deep learning-based predictive models, molecular simulations, and chemically aware language models. It accelerates candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization.

The Series B raise brings Genesis’ total capital raised since inception to over $280M.